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Abstract
Pomegranate juice (PJ; also known as pomegreat pure juice) provides a rich and varied source of polyphenolic compounds that may offer cardioprotective,
anti-atherogenic and antihypertensive effects. The aim of this study was to investigate the effect of PJ consumption on glucocorticoids levels, blood
pressure (BP) and insulin resistance in volunteers at high CVD risk. Subjects (twelve males and sixteen females) participated in a randomised, placebo-
controlled cross-over study (BMI: 26·77 (SD 3·36) kg/m2; mean age: 50·4 (SD 6·1) years). Volunteers were assessed at baseline, and at weeks 2 and 4
for anthropometry, BP and pulse wave velocity. Cortisol and cortisone levels in urine and saliva were determined by speciﬁc ELISA methods, and the
cortisol/cortisone ratio was calculated. Fasting blood samples were obtained to assess plasma lipids, glucose, insulin and insulin resistance (homeostasis
model assessment of insulin resistance). Volunteers consumed 500 ml of PJ or 500 ml of a placebo drink containing a similar amount of energy.
Cortisol urinary output was reduced but not signiﬁcant. However, cortisol/cortisone ratios in urine (P= 0·009) and saliva (P= 0·024) were signiﬁcantly
decreased. Systolic BP decreased from 136·4 (SD 6·3) to 128·9 (SD 5·1) mmHg (P= 0·034), and diastolic BP from 80·3 (SD 4·29) to 75·5 (SD 5·17) mmHg
(P= 0·031) after 4 weeks of fruit juice consumption. Pulse wave velocity decreased from 7·5 (SD 0·86) to 7·44 (SD 0·94) m/s (P= 0·035). There was also a
signiﬁcant reduction in fasting plasma insulin from 9·36 (SD 5·8) to 7·53 (SD 4·12) mIU/l (P= 0·025) and of homeostasis model assessment of insulin resistance
(from 2·216 (SD 1·43) to 1·82 (SD 1·12), P = 0·028). No signiﬁcant changes were seen in the placebo arm of the study. These results suggest that PJ consump-
tion can alleviate key cardiovascular risk factors in overweight and obese subjects that might be due to a reduction in both systolic and diastolic BP, possibly
through the inhibition of 11β-hydroxysteroid dehydrogenase type 1 enzyme activity as evidenced by the reduction in the cortisol/cortisone ratio. The reduction
in insulin resistance might have therapeutic beneﬁts for patients with non-insulin-dependent diabetes, obesity and the metabolic syndrome.
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CVD is a major cause of mortality in Western countries, par-
ticularly in Scotland where death rates are among the highest in
the world. Dietary factors represent a key component of the
disease and speciﬁc dietary constituents are considered to be
important to health. Polyphenols are secondary metabolites
widespread in the plant kingdom and form an integral part
of the human diet where it has been estimated that their
total dietary intake may be as high as 1 g/d(1). Polyphenols
have perceived health beneﬁts in their ability to neutralise
free radicals and reactive oxygen species, and thus cardiovas-
cular health may be improved, as LDL-cholesterol has a
reduced capacity to be oxidised and therefore to reduce
Abbreviations: 11β-HSD, 11β-hydroxysteroid dehydrogenase; BP, blood pressure; DBP, diastolic blood pressure; FRAP, ferric-reducing antioxidant power; HOMA-IR,
homeostasis model assessment of insulin resistance; PJ, pomegranate juice; SBP, systolic blood pressure.
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atherogenicity and platelet aggregation(2–4). The pomegranate
(Punica granatum L.) has been a medicinal food throughout his-
tory. Pomegranate juice (PJ; also known as pomegreat pure
juice) might have potent antioxidant and anti-atherosclerotic
properties attributed to its abundance of polyphenols including
ellagic acids, gallotannins and anthocyanins (cyanidin, delphini-
din and pelargonidin glycosides) and other ﬂavonoids. The
most abundant of these polyphenols is punicalagin, an ellagi-
tannin implicated as the bioactive constituent responsible for
>50 % of the juice’s antioxidant activity(5,6). Numerous studies
have been carried out for the identiﬁcation and quantiﬁcation
of phenolic compounds and their effects on antioxidant
activity of PJ in human subjects and animals(7–9), and have
concluded that most pomegranate ﬂavonoids and ellagitannins
such as punicalagin and ellagic acid can be detected in the
plasma and urine. However, the levels were found to be
lower than expected, which could be due to the fact that the
bioavailability process is complicated with large individual vari-
ations and requires further investigation using a large number of
volunteers. In addition, it was also discovered that even ellagic
acid metabolites such as urolithins A and B and their
glucuronide and sulphate derivatives are biologically active(10–12).
Several studies have demonstrated that consumption of
PJ can exert positive effects on cardiovascular risk, hyper-
tension, atherosclerosis, endothelial dysfunction and inﬂam-
mation(13–15). Clinical studies have shown a beneﬁcial effect
on vascular health following PJ consumption, with reduced
systolic blood pressure (SBP), enhanced antioxidant status
and improved insulin resistance in type 2 diabetic and hyper-
tensive patients(13,15,16). In addition, some researchers have
shown that PJ consumption reduces carotid intima-media
thickness and blood pressure (BP)(14,17). As powerful antioxi-
dants, phenolics may protect the body from damaging oxi-
dation reactions(18,19); however, other mechanisms may also
operate which are currently under investigation. In a limited
study of hypertensive patients, consumption of PJ for 2
weeks was shown to reduce SBP by inhibiting serum
angiotensin-converting enzyme(15). Obesity and diabetes are
other underlying factors linked to metabolic and cardiovascular
risk(14) as well as abnormal cortisol levels and metabolism(20).
The importance of cortisol in regulating BP has been high-
lighted in several conditions, and chronic excessive activation
of the glucocorticoid receptor is known to induce obesity,
insulin resistance, glucose intolerance and hypertension(21).
Glucocorticoids exert a direct effect on the heart and blood
vessels via 11β-hydroxysteroid dehydrogenase type 1 enzyme
(11β-HSD1) and 11β-HSD2. Increased 11β-HSD1 activity is
implicated in the development of the metabolic syndrome
and identifying dietary constituents that inﬂuence 11β-HSD1
activity could lead to novel methods of preventing CVD and
associated risk factors. The association between excess cortisol
and various parameters of the metabolic syndrome, including
hypertension and insulin resistance, is now increasingly recog-
nised(22,23). The aim of the present study was to examine the
inﬂuence of a 4-week consumption of PJ (Pomegreat Pure®)
containing 1685 mg/l polyphenols on salivary and urinary cor-
tisol and cortisone levels, and their ratio as indicative of the
activity of 11β-HSD enzymes. In addition, the assessment of
cardiometabolic risk factors: BP, arterial compliance, plasma
lipid proﬁle, glucose, insulin and insulin resistance, in a high-
risk group (age 40–65 years) of apparently healthy male and
female participants will be made.
Experimental methods
Study design
The study used a randomised, placebo-controlled, cross-over
design (Fig. 1). Following a 1-week run-in phase, eligible sub-
jects were randomly assigned to receive 500 ml PJ containing
1685 mg/l polyphenols or 500 ml placebo (water placed in a
dark container plus the addition of equivalent carbohydrates
to match the energy content of the juice). Participants followed
each intervention for 4 weeks, after which they were crossed
over to the next intervention separated by a 1-week washout
period. Participants were provided with a list of phenolic-rich
foods to avoid including green tea, red wine, dark chocolate
and berries. Compliance with the dietary restrictions was mon-
itored with a 3-d food diary record. Compliance was also
measured by assessing the total phenolic content of 24 h
urine samples collected at baseline, the mid-point and at the
end of the study period. All participants provided written
informed consent and a lifestyle questionnaire to determine
their eligibility. The study was conducted at Queen Margaret
University and the protocol was approved by Queen
Margaret University Research Ethics Committee. This study
was conducted according to the guidelines laid down in the
Declaration of Helsinki and all procedures involving human
subjects were approved by the Queen Margaret University
Research Ethics Central Committee. Written informed consent
was obtained from all subjects and has been recorded and
stored according to the university guidelines.
Inclusion and exclusion criteria
Participants were recruited by an email moderator advertisement
at Queen Margaret University, Edinburgh, UK. Volunteers were
aged between 40 and 65 years with a BMI between 25 and 35
kg/m2. Only those sedentary or moderately active (deﬁned as
Fig. 1. Flow diagram of the study design protocol.
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less than two aerobic sessions per week) were included.
Participants were excluded if they presented with signs of the
metabolic syndrome, i.e. fasting plasma glucose >6·1 mmol/l,
TAG level >1·7 mmol/l, low HDL-cholesterol (<1·01 mmol/
l for men and <1·25 mmol/l for women), hypertension, central
obesity (waist circumference >108 cm for men and >88 cm for
women) or if they had moderate hypercholesterolaemia.
Individuals were excluded also if they reported to have CVD,
diabetes, asthma, SBP >160 mmHg or diastolic blood pressure
(DBP) >99 mmHg. Individuals with thyroid gland disorders or
eating disorders, as well as those taking regular medication or
nutritional supplements (such as antioxidants or ﬁsh oil)
known to affect any dependent variable measured, were also
excluded.
Materials and chemicals
Gallic acid and Folin–Ciocalteau’s phenol regent were pur-
chased from Sigma. Methanol (HPLC grade) and HCl were
purchased from Rathburn Chemicals. Acetone, acetic acid
(glacial) and Na2HPO4 were obtained from Fisher Scientiﬁc.
Na2CO3, disodium hydrogen orthophosphate and sodium
dihydrogen orthophosphate dehydrate were purchased from
BDH Chemicals Ltd. All other chemicals and reagents were
obtained from Sigma unless otherwise stated.
Measurements
Fasted blood was collected at baseline and at the end of the
4-week intervention period. Plasma was obtained by centrifu-
gation (at 1500 g for 10 min) within 30 min of blood collection
and stored frozen at −80°C prior to analysis. Plasma lipids
and glucose analyses were undertaken at the Clinical
Biochemistry Laboratory, Western General Hospital,
Edinburgh, Scotland, UK using an automated platform
(Olympus). Fasting plasma insulin was estimated using a sen-
sitive human Insulin ELISA kit (GenWay), and insulin resist-
ance (homeostasis model assessment of insulin resistance
(HOMA-IR)) was calculated by the method of Turner and co-
workers(24) using the formula HOMA-IR = fasting glucose ×
fasting insulin/22·5. Unstimulated saliva samples were col-
lected (08.00 hours, noon and 18.00 hours) from volunteers
in sterile plastic containers at baseline and after 4 weeks of
the juice or placebo intake.
Serum NEFAwere quantiﬁed using an automated enzymatic
colorimetric method (Wako) at the Rowett Institute of
Nutrition and Health, Aberdeen, UK. Urinary and plasma
levels of total polyphenols(25) and ferric-reducing antioxidant
power (FRAP)(26) were measured by established methods.
Plasma levels of total phenolics were assessed by a modiﬁcation
of the Folin–Ciocalteau method as described by Seraﬁni
et al.(27). Cortisol and cortisone levels in saliva and urine samples
were estimated by using highly speciﬁc and sensitive ELISA
methods published previously(28). The ratio of cortisol to corti-
sone was calculated to give an indication of the activity of
11β-HSD1. All samples from the same subject were tested on
the same day to prevent any inter-day variation. A validated
automated A&D Medical UA-767 BP monitor (A&D
Medical) was used to measure BP according to Grassi
et al.(29). Three readings of BP were usually taken at each visit
and the average was calculated. Arterial compliance was
assessed by pulse wave velocity using a Vicorder™,
(Skidmore Medical), and again three measurements were
taken at each visit.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows, version 16.10 (SPSS Inc.). P ≤ 0·05 was considered
signiﬁcant. Continuous normally distributed data are expressed
as mean values and standard deviations unless otherwise sta-
ted. Differences in baseline characteristics were examined
using an independent-samples paired Student’s t test with
BMI, age, waist circumference, fasting insulin, glucose, lipid
proﬁle, BP, urinary and plasma total polyphenols and FRAP
as the dependent variables. ANOVA were conducted using
the general linear model procedure to assess the differences
in the effect of PJ and placebo on outcome measures. The
models included the main effects of treatment, time and treat-
ment–time interaction. Bonferroni adjustment was used to
account for multiple testing.
To examine whether the effect of PJ on BP, insulin and
HOMA-IR was dependent on BMI, we also ran a series of lin-
ear regression models. Changes in BP, insulin and HOMA-IR
were modelled as dependent variables. BMI, treatment and
BMI–treatment interaction were ﬁtted as predictors, as
shown in the following equation:
y = a1x1( ) + a2x2( ) + a3x3( ) + a4,
where y is the change in outcome from the baseline per person
per treatment group; x1 is the dummy variable, 0 for placebo
and 1 for PJ; x2 is the BMI expressed as a continuous variable;
x3 is the product term for dummy variable and BMI; and a1–4
is the β coefﬁcients.
Results
Subjects
Eligible participants were aged between 40 and 65 years with a
BMI between 25 and 35 kg/m2 (Table 1). In this randomised,
placebo-controlled, cross-over study, twenty-eight volunteers
(twelve males and sixteen females) completed the study and
each consumed 500 ml/d of PJ for a period of 4 weeks. Of
the total number recruited, eight were excluded for one of
the reasons mentioned in Fig. 1 and two subjects dropped
out of the study due to the inconvenience of travelling to
the university campus following baseline assessment.
Anthropometric and metabolic results
The 4-week intervention did not signiﬁcantly change plasma
levels of lipids (total cholesterol, TAG, LDL-cholesterol or
HDL-cholesterol) or glucose concentrations, which were all
within the anticipated physiological range (Table 1). There
was a signiﬁcant reduction in pulse wave velocity after 2
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weeks (P= 0·035) and 4 weeks of PJ consumption. There was
also a signiﬁcant reduction in both SBP and DBP in the treat-
ment group compared with the control group (Table 1), SBP
from 136·2 (SD 6·3) to 131·1 (SD 7·6) (P= 0·033) to 128·9 (SD
5·1) mmHg (P= 0·034) after 2 and 4 weeks, respectively.
DBP decreased from 80·27 (SD 4·29) to 75·5 (SD 5·17) mmHg
(P= 0·031) after 2 weeks of fruit juice consumption.
No signiﬁcant changes in body weight or BMI were
observed; however, eleven of the twenty-one participants
showed a decrease in plasma NEFA levels following fruit
juice consumption for 4 weeks (from 0·483 (SD 0·16) to
0·396 (SD 0·14) mmol/l, P = 0·017), and this was not observed
in the placebo group. Plasma antioxidant capacity was signiﬁ-
cantly increased following 4 weeks of PJ intake; FRAP
increased from 1098 (SD 170·5) to 1241 (SD 173·7) μmol Fe
(II)/l (P = 0·001) following fruit juice consumption. Plasma
total phenols were also signiﬁcantly increased from 3·23 (SD
0·41) to 3·48 (SD 0·46) mmol gallic acid equivalents/l (P =
0·015). Urinary antioxidant capacity was signiﬁcantly increased
following 2 and 4 weeks of PJ intake. After 2 weeks, the FRAP
level went up from 3·46 (SD 0·92) to 4·58 (SD 1·11) mmol Fe
(II)/d (P = 0·012). The urinary total phenolics level was also
signiﬁcantly increased from 2·59 (SD 0·71) to 3·33 (SD 0·81)
mmol gallic acid equivalents/d (P= 0·001). There was no sig-
niﬁcant change in the plasma lipid proﬁle, BP, fasting glucose
and insulin, plasma and urinary FRAP and total phenolics fol-
lowing the placebo arm of the study (Table 2).
Hormonal results
The results of cortisol and cortisone levels are shown in Fig. 2.
Urinary free cortisol levels were reduced following PJ con-
sumption compared to basal values, but not signiﬁcantly.
No signiﬁcant difference was obtained in urinary free
cortisone output. When the free cortisol/cortisone ratio was
calculated, there was a signiﬁcant reduction in urinary (P =
0·009) and salivary ratios (P= 0·024), indicating a possible
effect on 11β-HSD1 activity. Placebo data showed no signiﬁ-
cant difference (the urinary basal ratio was 1·029 (SD 0·28) and
post-placebo 1·042 (SD 0·34)). There was a signiﬁcant
reduction of fasting plasma insulin levels from 9·364 (SD
5·81) to 7·53 (SD 4·12) mIU/l (P= 0·025) and of insulin resist-
ance (HOMA-IR) from 2·216 (SD 1·43) to 1·825 (SD 1·12) (P=
0·028) (Table 1). There was no signiﬁcant change in all the par-
ameters tested following the placebo arm of the study (Table 2).
Blood pressure, insulin and homeostasis model of
insulin resistance results
The effect on SBP, DBP, insulin and HOMA-IR was also
studied using ANOVA. Here the changes in response between
the basal and the intervention (pomegranate or placebo) were
calculated, and the results are shown in Figs. 3 and 4. For BP
scores, the data were analysed using the differences between
the basal values and those following PJ or placebo intake.
Table 1. Anthropometric, pulse wave velocity (PWV), ferric-reducing antioxidant power (FRAP), total phenolics (TP), plasma cholesterol and lipid profile
measurements at baseline and following 2 and 4 weeks of pomegranate juice consumption
(Mean values and standard deviations)
Basal 2 weeks 4 weeks
Parameter Mean SD Mean SD P Mean SD P
Weight (kg) 79·02 13·1 78·71 13·9 0·057 78·9 13·3 0·337
BMI (kg/m2) 26·77 3·25 26·71 3·46 0·095 26·72 3·27 0·298
Systolic blood pressure (mmHg) 136·2 6·3 131·1 7·6 0·033 128·9 5·13 0·034
Diastolic blood pressure (mmHg) 80·27 4·29 75·5 5·17 0·031 76·2 4·89 0·039
PWV (m/s) 7·748 0·86 7·49 0·92 0·035 7·44 0·94 0·049
Urinary FRAP (mmol Fe2+/d) 3·46 0·92 4·58 1·11 0·012 4·32 0·91 0·031
Urinary TP (mmol gallic acid equivalents/d) 2·59 0·71 3·33 0·81 0·001 2·99 0·65 0·002
Plasma FRAP (mmol Fe2+/l) 1·1 0·17 1·24 0·17 0·001
Plasma TP (mmol gallic acid equivalents/l) 3·23 0·41 3·48 0·46 0·015
Plasma glucose (mmol/l) 4·89 0·37 4·81 0·53 0·437
Plasma insulin (mIU/l) 9·364 5·81 7·53 4·12 0·025
Total cholesterol (mmol/l) 5·34 0·77 5·45 1·0 0·52
HDL-cholesterol (mmol/l) 1·52 0·41 1·52 0·44 0·87
LDL-cholesterol (mmol/l) 3·28 0·71 3·31 0·73 0·23
TAG (mmol/l) 1·175 0·67 1·147 0·39 0·86
HOMA-IR 2·216 1·43 1·825 1·12 0·028
HOMA-IR, homeostasis model assessment of insulin resistance.
Table 2. Blood pressure (BP), pulse wave velocity (PWV), plasma
cholesterol and lipid profile measurements at baseline and following 4
weeks of placebo drink consumption
(Mean values and standard deviations)
Basal 4 weeks
Parameter Mean SD Mean SD P
Diastolic BP (mmHg) 78·9 11·1 80·9 10·9 0·397
Systolic BP (mmHg) 132·6 18·2 133·8 16·3 0·498
PWV (m/s) 7·62 0·78 7·54 0·94 0·249
Plasma TC (mmol/l) 4·58 0·47 4·51 0·51 0·742
Plasma HDL-C (mmol/l) 1·52 0·59 1·46 0·56 0·339
Plasma LDL-C (mmol/l) 2·52 0·69 2·54 0·79 0·993
Plasma TAG (mmol/l) 1·21 0·53 1·14 0·51 0·433
Plasma glucose (mmol/I) 4·65 0·48 4·74 0·27 0·537
Plasma insulin (mIU/l) 10·65 9·12 10·54 7·72 0·737
HOMA-IR 2·245 0·23 2·226 0·12 0·937
TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; HOMA-IR,
homeostasis model assessment of insulin resistance.
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The effects of PJ intake compared with the placebo were sig-
niﬁcant for all the variables when both males and females were
pooled (Fig. 3). Separately, the effects in males were not always
signiﬁcant, but in females, the differences were. For the effect
on plasma insulin and HOMA-IR (Fig. 4), the percentage
differences from basal values were analysed (e.g. 100 × basal
insulin/insulin PJ and 100 × basal insulin/insulin placebo).
Again, the results indicate that a signiﬁcance effect was more
apparent when all the data were pooled together.
Fig. 5. Association between BMI and changes in systolic blood pressure
(SBP) (a) or diastolic blood pressure (DBP) (b) following intake of pomegra-
nate juice (♦) or placebo ( ). The graph shows trend lines for pomegranate
juice (. . . .) and placebo (- - -). There was a significant interaction between
BMI and treatment for SBP (P = 0·013) and DBP (P = 0·022).
Fig. 2. Glucocorticoid results. (a) Urinary free cortisol and cortisone outputs at
baseline (■) and post-pomegranate juice (PJ; ▒) and (b) urinary (▓) and sali-
vary (///) free cortisol/cortisone ratios. Values are means, with standard errors
represented by vertical bars. Mean value was significantly reduced following
pomegranate juice intake compared with baseline: * P = 0·024, ** P = 0·009.
Fig. 4. Effect of pomegranate juice consumption on insulin (a) and homeosta-
sis model assessment of insulin-resistance (HOMA-IR) (b) calculated as per-
centage difference from basal values. Values are means, with standard errors
represented by vertical bars. There were significant reductions in percentage
fasting plasma insulin differences in females and pooled data but not in
males. However, there were significant reductions in percentage of HOMA-
IR differences for males, females and pooled data. * P < 0·05, ** P < 0·01,
*** P < 0·001.
Fig. 3. Effect of pomegranate juice consumption on blood pressure (BP)
reduction. There were significant reductions in systolic BP (a) and diastolic
BP (b) differences from basal values when both male and female data were
pooled. Separate effects in males were not always significant, but those in
females were. Values are means, with standard errors represented by vertical
bars. * P < 0·05, ** P < 0·01.
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For the results of linear regression models investigating
whether the effects of PJ on BP, insulin and HOMA-IR were
dependent on BMI, we also ran a series of regression analyses
between the changes in BP, insulin and HOMA-IR and BMI.
The association between BMI and changes in SBP or DBP
following intake of PJ or placebo (Fig. 5) showed a signiﬁcant
interaction between BMI and treatment for SBP (P = 0·013)
and DBP (P= 0·022). On the other hand, the association
between BMI and changes in insulin and HOMA-IR following
the intake of PJ or placebo (Fig. 6) showed that there was no
signiﬁcant interaction between BMI and treatment for insulin
(P= 0·469) or HOMA-IR (P = 0·431).
Discussion
The present study was conducted to investigate the cardio-
metabolic effects of PJ consumption over a 4-week period in
apparently healthy male and female participants at high CVD
risk. Previous clinical studies have shown beneﬁcial effects
on cardiovascular risk: reduced SBP, improved insulin resist-
ance in non-insulin-dependent diabetes mellitus and hyper-
tensive patients following the consumption of PJ(15,16,30,31).
Similarly, we also observed a signiﬁcant reduction in SBP
and DBP following 2 and 4 weeks of PJ consumption. The
drop in SBP was from 0·5 to 22 mmHg and the drop in
DBP was from 0 to 12 mmHg. Those with higher baseline
BP had the most marked drop in their BP following PJ con-
sumption (e.g. for subject 16, BP decreased from 160/91 to
141/74 compared with subject 1 from 135/64 to 130/61).
One of the main objectives of this study was to investigate
whether the drop in BP might be caused by inactivation of
11β-HSD1, which converts cortisone to the active steroid, cor-
tisol. The circulating level of cortisol is an important factor in
BP regulation and can also exert negative effects on the cardi-
ovascular system at an autocrine level. There are two isozymes
of 11β-HSD that catalyse the interconversion of active cortisol
and inactive cortisone. 11β-HSD1 is mostly abundant in liver
and adipose human tissue. It functions mainly as an oxoreduc-
tase converting cortisone to cortisol. We have shown that PJ
intake has the potential for inhibiting 11β-HSD1 activity as is
evident from the reduction in the cortisol/cortisone ratio in
both urine and saliva. The role of this enzyme in hypertension
has been reported previously, for example, in the syndrome of
apparent mineralocorticoid excess(32). A combination of assay-
ing urinary free cortisone and free cortisol is a powerful
method of assessing 11β-HSD1 activity that proved to be
very advantageous in this regard(33). However, we could not
directly assess the enzyme activity in this study (by PCR
expression for example) due to protocol limitations. In
addition, it has been postulated that selective inhibitors of
11β-HSD1 may lower blood glucose and HOMA-IR in type
2 diabetic animal models(34). Cortisol is known to be essential
for the long-term maintenance of blood glucose and could
also unfavourably inﬂuence BP and lipid proﬁle as it can induce
oxidative stress that has been linked to hyperinsulinaemia and
insulin resistance(22,23). This might explain our ﬁndings that
PJ consumption has improved insulin resistance in our cohort.
In this study, there was a reduction in free cortisol levels but it
was not signiﬁcant. Further investigation to establish whether
tissue-speciﬁc alteration in 11β-HSD1 occurs following PJ con-
sumption, in particular the effects on liver and adipose tissues,
would be warranted. It is widely accepted that obesity is an
inﬂammatory condition that may play an important role in
hypertension(35,36). Linear regression analysis of our results
has shown that there was a signiﬁcant interaction between
BMI and the reduction in SBP and DBP following PJ intake.
The drop in BP might also be partly explained by the inhibition
of angiotensin-converting enzyme activity following PJ intake
as reported by Aviram & Dornﬁeld(15), a reduction in carotid
intima-media thickness(14,17), an improvement of arterial elas-
ticity (as we have observed in this study) or a combination of
all these factors.
We did not ﬁnd any signiﬁcant changes in plasma total
cholesterol, HDL, LDL or TAG following PJ intake, which
was similar to the placebo results. This could be due to the
small number of participants and their age group or the
short washout period (1 week) that perhaps was not enough
for levels to go to baseline. We accept that this can be regarded
as one limitation of this study. However, studies conducted in
both human subjects and animals have shown conﬂicting
results. While some studies demonstrated a reduction in
TAG and total cholesterol levels following PJ consumption
(3–10 %), other studies have found no effects on circulating
lipids(37). However, several studies have consistently found a
reduction in oxidised LDL levels and plaque formation associ-
ated with atherosclerosis following PJ consumption(3,38,39).
Fig. 6. Association between BMI and changes in insulin (a) and homeostasis
model assessment of insulin resistance (HOMA-IR) (b) following intake of
pomegranate juice (♦) or placebo ( ). The graph shows trend lines for pome-
granate juice (. . . .) and placebo (- - -). There was no significant interaction
between BMI and treatment for insulin (P = 0·469) or HOMA-IR (P = 0·431).
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As powerful antioxidants polyphenols present in fruits may
help protect the body from damaging oxidation reactions;
however, the mechanism by which antioxidants exert their
effects is not fully understood. Certainly, antioxidants play a
key role in the scavenging of free radicals generated through
oxidative metabolism and may offer protection to bio-
molecules (DNA, lipids and proteins) against damage.
However, there is increasing evidence that individual phenolics
or certain classes of phenolics may exert additional beneﬁcial
effects independent of their antioxidant properties. Among
these are the deceleration of prostate cancer(40), anticancer
effect in human breast cancer(41), enhancement of NO biologi-
cal actions(42) and Alzheimer’s disease prevention(43).
In addition, phenolic extracts from plants were suggested to
cause insulin-like effects in glucose utilisation, and effectively
inhibit intestinal α-glucosidase activity. The inhibitory effec-
tiveness of the extracts were thought to be related to their
anthocyanin content, in particular diacylated anthocyanins
from these sources that were most effective(44). Moreover, cer-
tain phenolics also inhibit α-amylase activity, which could
prove synergistic to their potential therapeutic effect on post-
meal blood glucose levels. Tannins and ellagic acid in particu-
lar are potent inhibitors of α-amylase activity. Tannic acid and
tannin-rich non-alcoholic components of red wine have been
shown to reduce serum glucose levels following a starch-rich
meal in patients with non-insulin-dependent diabetes melli-
tus(45). A recent review of the role of antioxidants in abnormal
glucose metabolism(46) has concluded that experimental data
are in favour of a beneﬁcial role, but clinical data in human
subjects remain controversial.
The question of bioavailability of pomegranate polyphenols
remains controversial. Some authors have concluded that
phenolic compounds such as those present in pomegranate
are poorly absorbed and do not markedly contribute to anti-
oxidant activity(47,48). However, an overwhelming number of
studies have shown demonstrable health beneﬁts following
the consumption of PJ or extract mainly due to the biotrans-
formation of pomegranate polyphenols(3–8,13,37–39,41–44).
There is also now good evidence that even ellagitannin
metabolites such as urolithins A, B and C and their glucuro-
nides and sulphates are biologically active(10–12). In the pre-
sent study, we observed signiﬁcant reductions in both
insulin and insulin resistance (HOMA-IR) following PJ con-
sumption. Diabetic patients may be more prone to oxidative
stress because as hyperglycaemia facilitates the production of
free radicals(49), dietary antioxidants may be important thera-
peutically in the control of non-insulin-dependent diabetes
mellitus. There have been reports that naturally occurring
polyphenols can inhibit pancreatic lipase and thereby inﬂu-
ence fat digestion and affect energy intake. A recent study
investigated the effects of different berry phenolic extracts
on their ability to inhibit pancreatic lipase in vitro(50). The
most effective were from the Rubus family (i.e. raspberry,
cloudberry and bramble) and strawberry. There is also a sug-
gestion that ellagitannins present in berries and pomegranate
could be important for lipase inhibition. Commercial PJ is
known to contain signiﬁcant levels of both ellagitannins
and anthocyanins which may inﬂuence fat digestion and
excretion. Although we did not investigate the inﬂuence of
PJ on pancreatic lipase activity in vitro, future studies will
focus on this important aspect. In the present study, we
did not ﬁnd a signiﬁcant reduction in overall body weight;
however, we did observe a trend towards a reduction
in waist circumference and plasma NEFA in some of our
subjects. The role of NEFA in human obesity appears to
be important, and experimental evidence links the NEFA-
induced presser response to sympathetic activation(51).
Abdominal obesity is linked to increased NEFA levels,
which are associated with an increase in BP and seem to
be resistant to suppression by insulin(52–54).
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